DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor

BUDAPEST, Hungary, June 10, 2019 (GLOBE NEWSWIRE) — Druggability Technologies Holdings (DRGT) today announced results from a pharmacokinetic study of their novel formulation of celecoxib (“DRGT-46”), which achieves faster time to maximum plasma concentration (Tmax) compared to traditional celecoxib capsules.

The pharmacokinetic profile for DRGT-46 was evaluated in adult subjects after a single 100-mg (30 min to Tmax) or 200-mg (45 min to Tmax) dose of DRGT-46 compared to a single 200-mg (180 min to Tmax) Celebrex® dose. There were no significant safety issues and all adverse effects were mild and unrelated to study drugs. “This phase 1 study demonstrates the enhanced absorption, earlier Tmax, and up to 6-times earlier attainment of therapeutic plasma concentrations of celecoxib with DRGT-46 compared to the branded product, Celebrex®,” said John Friend M.D., Chief Medical Officer for DRGT-USA. “We are working to initiate a pivotal phase 3 program in adults with acute pain and continuing to explore other development options for both adult and pediatric populations.”

About DRGT-46

DRGT-46 is designed to enhance the absorption rate for celecoxib, leading to faster attainment of therapeutic plasma concentrations to provide more rapid and consistent pain relief. DRGT-46 dissolves easily into 100-200 ml tap water for oral administration, and taste profile testing confirmed patient preference for DRGT-46. Celecoxib (Celebrex®) is a nonsteroidal anti-inflammatory inhibitor of cyclooxygenase-2 (COX-2) available in capsule form that is indicated for management of acute pain, osteoarthritis, rheumatoid arthritis, primary dysmenorrhea, and juvenile idiopathic arthritis (JIA).

About DRGT

DRGT is a specialty pharmaceutical company dedicated to the development and commercialization of high-value proprietary drugs that deliver measurable and meaningful improvements in clinical utility. DRGT utilizes its proprietary Super-API drug development platform to rapidly select, screen and develop drugs with enhanced pharmacokinetics which could lead to improved efficacy and safety. Super-APIs are proprietary drug compositions that are developed by DRGT’s drug development platform comprising the Compound(s) molecularly dispersed in a supramolecular polymer(s) and/or excipient(s) matrix. The Company’s Super-API portfolio contains 30 compounds across a variety of indications and are protected by global composition of matter Intellectual Property. The company was founded by Dr. Ferenc Darvas, who is also the Chairman of the oldest Hungarian upstream-technology network.

Gábor Heltovics, CEO
E-mail: [email protected]
Phone: +36-1-5779-300

Celebrex® is a registered product of Pfizer

DRGT Technologies Holdings has no ownership interest in Pfizer

Forward Looking Statements:

In the interests of providing Druggability Technologies’ or its subsidiaries’ (together, the “Company”) potential partners and investors with information regarding the Company, including the Company’s objectives, goals and strategies, certain statements included in this material may constitute forward-looking information or forward looking statements (collectively, “forward-looking statements”). All statements contained herein that are not clearly historical in nature are forward-looking, and the words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. The Company cautions readers not to place undue reliance on these statements as a number of important factors, many of which are beyond the Company’s control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to, the applicability of patents and proprietary technology; possible patent litigation; regulatory approval of products in the Company’s pipeline; changes in government regulation or regulatory approval processes; government and third-party player reimbursement; dependence on strategic partnerships for product candidates and technologies, marketing and R&D services; meeting projected drug development timelines and goals; intensifying competition; rapid technological change in the pharmaceutical industry; anticipated future losses; the ability to access capital to fund R&D; and the ability to attract and retain key personnel.

The foregoing list of important factors that may affect future results is not exhaustive. When reviewing the presented forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by the Company or on its behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.